Momentum Public Relations
Press Release: October 15, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the permanent appointment of Guy Chamberland, Ph.D., as CEO and CSO having most recently held the position of CEO in an interim capacity. Dr. Chamberland has more than 23 years’ experience in the development of new drugs in the North American pharmaceutical industry. He worked for more than 10 years as an executive with several biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years. Since joining Tetra Bio-Pharma in June 2016, Dr. Chamberland and his team have accomplished numerous milestones. These include having:
- Built a solid pipeline of five cannabinoid-based therapeutics using a variety of delivery mechanisms focused on a number of different disease indications many representing billion dollar markets;
- Developed an innovative regulatory strategy for each of these products to maximize approval success – thereby rapidly building shareholder value;
- Taking Tetra’s lead product PPP001 from concept to Phase 3 in less than two years and at 20 percent of the cost of a typical bio-pharma company;
- Taken the first smokable product into a Phase I and Phase III clinical trial;
- Structured company activities in three distinct commercial divisions: bio-pharma, natural health and veterinary medicine;
- Negotiated a major supply agreement with a well-established player in the natural health products market; and
- Increased the company’s share price more than 50% since assuming the role of interim CEO.
“We are extremely pleased with the progress that Guy has made since joining the company in 2016 and equally impressed with his accomplishments since being named interim CEO,” stated Tetra Bio-Pharma’s Chairman of the Board, Bill Cheliak. “It is for these reasons that the Board unanimously voted to permanently appoint Guy to the position of CEO, along with his role as Chief Scientific Officer. We look forward to seeing Guy and his team build on the tremendous momentum they have generated thus far and continue to increase shareholder value.”
“I am greatly honored by this nomination as well as by the confidence that the Board of Directors has shown in me,” said Dr. Chamberland. “As the CEO of Tetra Bio-Pharma I am excited and deeply committed to lead our team through the next stages of development. We are confident that our innovative pipeline of cannabis and cannabinoid products will play an important role in improving the lives of patients suffering from a range of chronic and acute pain conditions and have a significant impact in opioid sparing and/or replacement. It is evident that the pharmaceutical pathway that we are championing in order to establish the scientific evidence that regulators, the medical community and payers in Canada, the United States and Europe require in order to approve cannabis-based products is becoming better understood and increasingly welcomed. Our robust activity in the natural health sector further demonstrates our capacity for innovation.”
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma